Creating New and Better Biopharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease.
Latest News
- PhaseBio Expands Clinical Development of Vasomera, an Investigational Treatment for Cardiopulmonary Diseases
- PhaseBio Initiated Phase 1 Study of Investigational Once-Weekly Basal Insulin For Potential Treatment of Diabetes
- PhaseBio to Present at the Jefferies 2013 Global Healthcare Conference
- PhaseBio Positions for the Next Stage of Development by Bringing on Board Industry Veteran, Jonathan Mow as CBO